RLIP76 Found to Mediate Pancreatic Cancer Cell Resistance to Chemotherapy and Radiation

Share this content:

(ChemotherapyAdvisor) – The multifunctional cell membrane protein RLIP76 represents a mechanistically significant target for developing effective interventions for pancreatic cancers resistant to chemotherapy and radiation, according to results of a study presented June 19 at the American Association for Cancer Research's Pancreatic Cancer: Progress and Challenges conference, Lake Tahoe, NV.

The study determined whether targeted depletion of RLIP76, expression of which is elevated in pancreatic cancer cells, represented an effective antineoplastic therapy that could overcome chemotherapy and radiation resistance in pancreatic cancer and whether the PI3K/AKT signaling pathway is affected. Previously, in-vitro studies have indicated a role for PI3K/AKT as mechanisms of apoptosis resistance in pancreatic cancer, and inhibition of RLIP76 has been shown to antagonize both PI3K and AKT in other cancers, noted Sanjay Awasthi, MD, of City of Hope Comprehensive Cancer Center, Duarte, CA.

The investigators found RLIP76 depletion caused marked and sustained regression of established human BxPC-3 pancreatic cancer tumors in a nude mouse xenograft model, and confirmed the ability of RLIP76 to mediate drug and radiation resistance.

“Results of signaling studies are consistent with an encompassing model for the role of RLIP76 in regulating the levels of fundamental proteins like PI3K, AKT, E-cadherin, CDK4, Bcl2 and PCNA,” Leake concluded.

According to Dr. Awasthi, one added benefit to depleting levels of RLIP76 in the mice with established tumors was a decrease in blood glucose, cholesterol, and triglycerides. “These findings indicate that it might be possible to develop a single class of medications that have potent antidiabetic and anticancer effects,” he said.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs